8-K: Syndax Pharmaceuticals Reports Positive Clinical Progress and Strong Financial Position in 2023

Syndax Pharmaceuticals announced its fourth quarter and full year 2023 financial results, highlighting significant clinical and regulatory advancements, including BLA filing for axatilimab and NDA submission for revumenib.

Summary

• Syndax Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2023, alongside a clinical and business update.
• The company submitted a New Drug Application (NDA) for revumenib for the treatment of relapsed or refractory KMT2A-rearranged acute leukemia, which is under FDA review.
• The Biologics License Application (BLA) for axatilimab for chronic graft-versus-host disease (GVHD) has been granted Priority Review with a PDUFA action date set for August 28, 2024.
• Enrollment in the AUGMENT-101 trial for mNPM1 acute myeloid leukemia is expected to complete in late Q1 or early Q2 2024, with topline data expected in Q4 2024.
• Syndax initiated a Phase 1 trial of revumenib in combination with chemotherapy for newly diagnosed acute leukemias.
• The company has $600.5 million in cash and cash equivalents, which is expected to fund operations through 2026.
• Research and development expenses for the full year 2023 were $163.0 million, compared to $118.5 million in 2022.
• Selling, general, and administrative expenses for the full year 2023 were $66.9 million, compared to $33.3 million in 2022.
• The net loss attributable to common stockholders for the full year 2023 was $209.4 million, or $2.98 per share, compared to $149.3 million, or $2.46 per share, in 2022.
• The company expects research and development expenses to be between $240 and $260 million and total operating expenses to be between $355 and $375 million for the full year 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant clinical and regulatory progress, a strong cash position, and clear future milestones. However, the increased losses and expenses temper the overall sentiment slightly.

Positives

• The company has a strong cash position of $600.5 million, expected to fund operations through 2026.
• Both axatilimab and revumenib are progressing through regulatory pathways with key PDUFA dates expected.
• Multiple clinical trials are underway for revumenib, including combination therapies.
• The company has secured Priority Review for axatilimab, which could expedite its approval.
• Syndax has a co-commercialization agreement with Incyte for axatilimab in the U.S.

Negatives

• The company reported a net loss of $209.4 million for the full year 2023, which is an increase from the $149.3 million loss in 2022.
• Research and development expenses increased significantly in 2023, reaching $163.0 million compared to $118.5 million in 2022.
• Selling, general, and administrative expenses also increased substantially in 2023, reaching $66.9 million compared to $33.3 million in 2022.

Risks

• Clinical trial results may not be positive or may not lead to regulatory approvals.
• The company's financial performance is dependent on the success of its clinical programs and commercialization efforts.
• There are risks associated with the regulatory approval process, including potential delays or rejections.
• The company faces competition from other pharmaceutical companies developing cancer therapies.
• Unexpected safety or efficacy data observed during preclinical or clinical trials could impact the company's prospects.

Future Outlook

Syndax expects to complete enrollment in the AUGMENT-101 trial in late Q1 or early Q2 2024, with topline data expected in Q4 2024. The company anticipates a PDUFA action date for revumenib in the first quarter of 2024. Syndax believes it has sufficient cash to fund operations through 2026.

Management Comments

• 2023 was a landmark year for Syndax marked by execution across all of our major clinical, regulatory, and operational milestones, said Michael A. Metzger, Chief Executive Officer.
• With the axatilimab BLA filing under FDA Priority Review and receipt of a PDUFA action date for revumenib anticipated later this quarter, preparations are well underway for the potential launch of both firstand best-in-class drugs later this year.
• We are committed to maximizing the full potential of these therapies beyond their initial approvals through expansion into earlier lines of therapy in combination with standard of care agents and into new indications.
• With a strong cash position that is expected to fund operations through 2026, Syndax is well positioned for continued success and long-term growth.

Industry Context

This announcement reflects the ongoing progress in the biopharmaceutical industry towards developing targeted therapies for cancer and other diseases. The focus on combination therapies and expansion into new indications is a common trend in the industry. The use of the FDA's RTOR program highlights the industry's push for faster regulatory approvals.

Comparison to Industry Standards

• Syndax's cash position of $600.5 million is relatively strong compared to other clinical-stage biopharmaceutical companies, providing a runway through 2026.
• The increase in R&D expenses is typical for companies advancing multiple clinical programs, similar to companies like Agios Pharmaceuticals and Blueprint Medicines.
• The submission of NDAs and BLAs is a key milestone for biopharmaceutical companies, comparable to filings by companies like Deciphera Pharmaceuticals and Kura Oncology.
• The use of the FDA's RTOR program is a positive sign, aligning with industry efforts to expedite drug approvals, similar to other companies in the oncology space.
• The co-commercialization agreement with Incyte for axatilimab is a common strategy for smaller biopharma companies, similar to partnerships seen with companies like Arcus Biosciences and Exelixis.

Stakeholder Impact

• Shareholders may view the clinical and regulatory progress positively, but the increased losses may be a concern.
• Employees may be encouraged by the company's growth and progress.
• Patients may benefit from the potential approval of new therapies.
• The company's financial stability may reassure suppliers and creditors.

Next Steps

• The company expects to receive a PDUFA action date for revumenib in the first quarter of 2024.
• Enrollment in the AUGMENT-101 trial is expected to complete in late Q1 or early Q2 2024.
• Topline data from the AUGMENT-101 trial is expected in Q4 2024.
• Incyte plans to initiate two combination trials with axatilimab in chronic GVHD in mid-2024.
• The company plans to initiate a pivotal trial of revumenib in combination with venetoclax and azacitidine in newly diagnosed mNPM1 or KMT2Ar acute leukemia patients unable to receive intensive chemotherapy by year-end 2024.

Key Dates

Keywords

Syndax Pharmaceuticals, axatilimab, revumenib, cancer therapy, acute leukemia, graft-versus-host disease, clinical trials, FDA, PDUFA, biopharmaceutical